These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 15279078)

  • 1. Evaluation of two replacement regimens in primary adrenal insufficiency patients. effect on clinical symptoms, health-related quality of life and biochemical parameters.
    Alonso N; Granada ML; Lucas A; Salinas I; Reverter J; Oriol A; Sanmarti A
    J Endocrinol Invest; 2004 May; 27(5):449-54. PubMed ID: 15279078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, crossover study comparing two- and four-dose hydrocortisone regimen with regard to quality of life, cortisol and ACTH profiles in patients with primary adrenal insufficiency.
    Ekman B; Bachrach-Lindström M; Lindström T; Wahlberg J; Blomgren J; Arnqvist HJ
    Clin Endocrinol (Oxf); 2012 Jul; 77(1):18-25. PubMed ID: 22288685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of addison's disease: a randomized clinical trial.
    Oksnes M; Björnsdottir S; Isaksson M; Methlie P; Carlsen S; Nilsen RM; Broman JE; Triebner K; Kämpe O; Hulting AL; Bensing S; Husebye ES; Løvås K
    J Clin Endocrinol Metab; 2014 May; 99(5):1665-74. PubMed ID: 24517155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circadian hormone profiles and insulin sensitivity in patients with Addison's disease: a comparison of continuous subcutaneous hydrocortisone infusion with conventional glucocorticoid replacement therapy.
    Björnsdottir S; Øksnes M; Isaksson M; Methlie P; Nilsen RM; Hustad S; Kämpe O; Hulting AL; Husebye ES; Løvås K; Nyström T; Bensing S
    Clin Endocrinol (Oxf); 2015 Jul; 83(1):28-35. PubMed ID: 25400085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of Time-Point Serum Cortisol and ACTH Measurements for the Adjustment of Glucocorticoid Replacement in Adrenal Insufficiency.
    Rousseau E; Joubert M; Trzepla G; Parienti JJ; Freret T; Vanthygem MC; Desailloud R; Lefebvre H; Coquerel A; Reznik Y;
    PLoS One; 2015; 10(8):e0135975. PubMed ID: 26317782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel strategies for hydrocortisone replacement.
    Debono M; Price JN; Ross RJ
    Best Pract Res Clin Endocrinol Metab; 2009 Apr; 23(2):221-32. PubMed ID: 19500765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing glucocorticoid replacement therapy in severely adrenocorticotropin-deficient hypopituitary male patients.
    Behan LA; Rogers B; Hannon MJ; O'Kelly P; Tormey W; Smith D; Thompson CJ; Agha A
    Clin Endocrinol (Oxf); 2011 Oct; 75(4):505-13. PubMed ID: 21521342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated hair cortisol concentrations in children with adrenal insufficiency on hydrocortisone replacement therapy.
    Noppe G; van Rossum EF; Vliegenthart J; Koper JW; van den Akker EL
    Clin Endocrinol (Oxf); 2014 Dec; 81(6):820-5. PubMed ID: 25039686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose distribution in hydrocortisone replacement therapy has a significant influence on urine free cortisol excretion.
    Bliesener N; Steckelbroeck S; Redel L; Klingmüller D
    Exp Clin Endocrinol Diabetes; 2003 Oct; 111(7):443-6. PubMed ID: 14614652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of short-term nocturnal cortisol replacement on cognitive function and quality of life in patients with primary or secondary adrenal insufficiency: a pilot study.
    Harbeck B; Kropp P; Mönig H
    Appl Psychophysiol Biofeedback; 2009 Jun; 34(2):113-9. PubMed ID: 19387826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An assessment of optimal hydrocortisone replacement therapy.
    Howlett TA
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):263-8. PubMed ID: 9156032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous subcutaneous hydrocortisone infusion therapy in Addison's disease: a randomized, placebo-controlled clinical trial.
    Gagliardi L; Nenke MA; Thynne TR; von der Borch J; Rankin WA; Henley DE; Sorbello J; Inder WJ; Torpy DJ
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4149-57. PubMed ID: 25127090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychological morbidity and impaired quality of life in patients with stable treatment for primary adrenal insufficiency: cross-sectional study and review of the literature.
    Tiemensma J; Andela CD; Kaptein AA; Romijn JA; van der Mast RC; Biermasz NR; Pereira AM
    Eur J Endocrinol; 2014 Aug; 171(2):171-82. PubMed ID: 24801589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency.
    Mah PM; Jenkins RC; Rostami-Hodjegan A; Newell-Price J; Doane A; Ibbotson V; Tucker GT; Ross RJ
    Clin Endocrinol (Oxf); 2004 Sep; 61(3):367-75. PubMed ID: 15355454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma, salivary and urinary cortisol levels following physiological and stress doses of hydrocortisone in normal volunteers.
    Jung C; Greco S; Nguyen HH; Ho JT; Lewis JG; Torpy DJ; Inder WJ
    BMC Endocr Disord; 2014 Nov; 14():91. PubMed ID: 25425285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of treatment of primary adrenal insufficiency by administration of cortisone acetate in three daily doses.
    Laureti S; Falorni A; Santeusanio F
    J Endocrinol Invest; 2003 Nov; 26(11):1071-5. PubMed ID: 15008243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency.
    Bleicken B; Hahner S; Loeffler M; Ventz M; Decker O; Allolio B; Quinkler M
    Clin Endocrinol (Oxf); 2010 Mar; 72(3):297-304. PubMed ID: 19508599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum cortisol and 17-hydroxyprogesterone interrelation in classic 21-hydroxylase deficiency: is current replacement therapy satisfactory?
    Charmandari E; Matthews DR; Johnston A; Brook CG; Hindmarsh PC
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4679-85. PubMed ID: 11600525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of standard glucocorticoid replacement therapies on subjective well-being: a randomized, double-blind, crossover study in patients with secondary adrenal insufficiency.
    Benson S; Neumann P; Unger N; Schedlowski M; Mann K; Elsenbruch S; Petersenn S
    Eur J Endocrinol; 2012 Nov; 167(5):679-85. PubMed ID: 22930487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of different regimens of glucocorticoid replacement therapy in patients with hypoadrenalism.
    Barbetta L; Dall'Asta C; Re T; Libè R; Costa E; Ambrosi B
    J Endocrinol Invest; 2005; 28(7):632-7. PubMed ID: 16218046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.